Anti-tumor compositions and methods

Adenovirus vectors expressing TGF-PRII-Fc, IFN-y, and IL-7 target desmoplasia and immunosuppression in PDAC, effectively reducing tumor growth and enhancing immune responses.

WO2026241418A2PCT designated stage Publication Date: 2026-11-19REGENTS OF THE UNIVERSITY OF MINNESOTA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028038
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Pancreatic ductal adenocarcinoma (PDAC) is refractory to current therapeutics due to desmoplasia and a highly immunosuppressive tumor microenvironment, leading to poor prognosis and limited treatment options.

Method used

Utilizing adenovirus vectors to express transgenes such as TGF-PRII-Fc, IFN-y, IL-7, and TIM3-Fc to target desmoplasia and immunosuppression, enhancing anti-tumor immune responses by inhibiting TIM3 signaling and increasing immune cell infiltration.

Benefits of technology

Significantly reduces tumor growth and desmoplasia, enhances immune cell infiltration, and induces abscopal effects, offering a novel therapeutic approach for PDAC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000024_0001_TABLE
    Figure IMGF000024_0001_TABLE
  • Figure IMGF000025_0001_TABLE
    Figure IMGF000025_0001_TABLE
  • Figure IMGF000027_0001_TABLE
    Figure IMGF000027_0001_TABLE
Patent Text Reader

Abstract

An adenovirus includes at least one transgene. In one or more embodiments, the adenovirus includes a polynucleotide encoding interferon gamma (IFN-y), a polynucleotide encoding an extracellular domain of transforming growth factor beta receptor 2 fusion protein (e.g., TGF-βRII-Fc), a polynucleotide encoding IL-7, and / or a polynucleotide encoding T cell immunoglobulin and mucin-domain containing-3 (TIM-3). In one or more embodiments, the adenovirus includes a polynucleotide encoding IFN-y and a polynucleotide encoding TGF-βRII-Fc.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PCT Patent Application Attorney Docket No. 0110.000776W001

[0002] ANTI-TUMOR COMPOSITIONS AND METHODS

[0003] CROSS REFERENCE TO RELATED APPLICATION

[0004] This application claims the benefit of U.S. Provisional Patent Application No.

[0005] 63 / 805,082, filed May 13, 2025, which is incorporated herein by reference in its entirety.

[0006] SEQUENCE LISTING

[0007] This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an xml file entitled

[0008] “0110_000776W001_ST26.xml” having a size of 23432 bytes and created on May 13, 2026. The information contained in the Sequence Listing is incorporated by reference herein.

[0009] SUMMARY

[0010] This disclosure describes, in one aspect, a fusion protein that includes a human T cell immunoglobulin and mucin-domain containing-3 (TIM-3) extracellular domain and an Fc antibody region domain (hsTIM3-Fc). In one or more embodiments, the fusion protein includes the amino acid sequence of SEQ ID NO:23.

[0011] In another aspect, this disclosure describes a fusion protein that includes the extracellular domain of transforming growth factor beta receptor 2 (TGF-PRII) and an Fc antibody region domain (TGF-PRII-Fc). In one or more embodiments, the fusion protein includes the amino acid sequence of SEQ ID NO:24.

[0012] In another aspect, this disclosure describes a vector engineered to express a fusion protein that includes a human T cell immunoglobulin and mucin-domain containing-3 (TIM-3) extracellular domain and an Fc antibody region domain. In one or more embodiments, the vector is an adenovirus that includes a polynucleotide that encodes the fusion protein.

[0013] In another aspect, this disclosure describes a pharmaceutical composition that includes an hsTIM3-Fc fusion protein and a pharmaceutically acceptable carrier.In another aspect, this disclosure describes a pharmaceutical composition that includes a vector engineered to express an hsTIM3-Fc fusion protein and a pharmaceutically acceptable carrier.

[0014] In another aspect, this disclosure describes a method of treating a subject having a tumor. Generally, the method includes administering to the subject a pharmaceutical composition that includes an hsTZM3-Fc fusion protein or a vector engineered to express an hsTIM3-Fc fusion protein in an amount effective to reduce the size of the tumor.

[0015] In another aspect, this disclosure describes a method of treating a subject having a tumor. Generally, the method includes administering to the subject a pharmaceutical composition that includes an hsTIM3-Fc fusion protein or a vector engineered to express an hsTIM3-Fc fusion protein in an amount effective to reduce the weight of the tumor.

[0016] In another aspect, this disclosure describes an adenovirus that includes at least one transgene. In one or more embodiments, the adenovirus includes a polynucleotide encoding human interferon gamma (hlFN-y), a polynucleotide encoding an extracellular domain of transforming growth factor beta receptor 2 fusion protein (e.g., TGF-PRII-Fc), a polynucleotide encoding IL-7, and / or a polynucleotide encoding T cell immunoglobulin and mucin-domain containing-3 (TIM-3). In one or more embodiments, the adenovirus includes a polynucleotide encoding IFN-y and a polynucleotide encoding TGF-PRII-Fc.

[0017] In one or more embodiments, at least one transgene is operably linked to and under expression control of a cytomegalovirus (CMV) promoter.

[0018] In another aspect, this disclosure describes a method of treating tumor is a subject.

[0019] Generally, the method includes administering the adenovirus expressing one or more transgenes to the subject in an amount effective for treating the tumor.

[0020] In one or more embodiments, the tumor is a refractory tumor. In one or more of these embodiments, the refractory tumor is pancreatic ductal adenocarcinoma (PDAC).

[0021] In one or more embodiments, the method further includes administering to the subject an additional anti -turn or therapy. In one or more of these embodiments, the additional anti -turn or therapy includes CAR T cells, a check point inhibitor, or T cell receptor engineered T cells.

[0022] The above summary is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance isprovided through lists of examples, which examples can be used in various combinations. Tn each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

[0023] BRIEF DESCRIPTION OF THE FIGURES FIG. 1. Schematic diagram of Human T cell Immunoglobulin and Mucin-domain containing-3 (hTIM-3).

[0024] FIG. 2. Schematic diagram showing anti-TIM3 monoclonal antibody blocking TIM3 signaling by inhibiting binding of phosphatidyl serine (PS) to TIM3.

[0025] FIG. 3. In vitro data showing hsTIM3-Fc decreases TIM3 signaling. hsTIM3-Fc had greater blocking capability than hsTIM3 (not fused to Fc) and the control monoclonal antibody FIG. 4. In vivo data showing expression of hsTIM3-Fc from an adenovirus vector within tumors decreases tumor growth. Subcutaneous tumors using KPC cells (mouse pancreatic cancer cell line) were established in C57BL / 6J immunocompetent mice. Tumors were injected with engineered adenovirus vector when tumors reached ~100 mm3. Expression of hsTIM3-Fc decreased the growth of tumors.

[0026] FIG. 5. Vector construction, expression, and biological activity of transgene-expressing Ad vectors. (A) Transgene-expressing replication-incompetent Ad constructs. Transgene cassettes driven by a CMV promoter were placed in the El region. (B) Transgene expression in KPC cells infected with increasing doses of Ad vectors. (C-F) Biological activity of each transgene. Supernatants from infected KPC cells were tested for mlFN-y (C), hsTGF-pRII-Fc (D), hIL-7 (E), and hsTIM3-Fc (F). *p < 0.05; **p < 0.005; ***p < 0.0005.

[0027] FIG. 6. Anti-tumor effects of intratumorally (i.t.) injected Ad vectors expressing transgenes in syngeneic mouse models with KPC cells. (A) Treatment schedule of Ad i.t. injection in C57BL / 6 mice harboring subcutaneous KPC cell tumors. (B) Antitumor effect of single transgene vectors. Tumors were measured every three days using digital calipers, and volume was recorded. (C) Tumor weight at the end of the experiment for single transgene vector treatment. (D) Representation of Ad construct expressing two transgenes, mlFN-y and hsTGF-PRII-Fc, separated by the self-cleaving T2A peptide. (E) Transgene expression in KPC cells infected with Ad-mIFNY-hsTGFpRII-Fc. (F) Antitumor effect of double transgene vector. (G) Tumor weight at the end of the experiment for double transgene vector treatment. (H) Kaplan-Meier Curve showing probability of survival for mice treated with each Ad construct. *p < 0.05; **p < 0.005; ***p < 0.0005.

[0028] FIG. 7. Intratumoral analysis of protein expression in Ad-treated tumors. (A) Intratumoral transgene expression of mlFN-y. (B) Intratumoral transgene expression of hIL-7. (C) Intratumoral transgene expression of hsTGF-pRII-Fc and hsTIM3-Fc. (D)-I. Intratumoral level of TNFa. (E). Intratumoral levels of IL-2. (F) Intratumoral levels of IFN-y. (G) Intratumoral levels of ILip. (H) Intratumoral levels of IL-10. (I) Intratumoral levels of TGF-pi. (J) Intratumoral levels of SMAD activation. The ratio of phosphorylated SMAD (pSMAD) to total SMAD (tSMAD) was measured as a representation of SMAD activation with ELISAs. *p < 0.05; **p < 0.005; ***p < 0.0005.

[0029] FIG. 8. Intratumoral immune cell analysis of treated tumors. (A) Number of infiltrating immune cells; Tumors were harvested on day 6 and stained for NK cells using anti-NK-1.1, CD4+T cells using anti-CD3 + anti-CD4, and activated CD8+T cells using anti-CD8 + anti-Granzyme B. Counted cells are represented with a corresponding bar graph for each immune cell subtype. (B) Representative images of immune cell staining. (C) The effect of immune cell depletion. Immune cells were depleted prior to virus treatment, and tumor volume was recorded. (D) Tumor weight. Tumor weights were measured at the end of the experiment. *p < 0.05; **p < 0.005; ***p < 0.0005.

[0030] FIG. 9. Measurement of fibrosis in tumors treated with Ads. (A) On day 6, tumors were harvested and stained with Masson’s Trichrome Stain. Whole tumor sections were quantified for collagen deposition (blue) and represented as a percentage of the entire tumor area.

[0031] Representative images for each treatment are shown. (B) Quantitation of fibrosis staining.

[0032] Collagen = blue, nuclei = purple, cytoplasm = pink. (C) Intratumoral levels of matrix metalloproteinase 9 (MMP9) measured via ELISA. *p < 0.05; **p < 0.005; ***p < 0.0005.

[0033] FIG. 10. Abscopal effects of Ad treatment in syngeneic mouse models. (A) Anti -tumor effect. Tumor volume was recorded for injected (left side) and noninjected (right side) tumors. (B) Tumor weight. Tumors were weighed at the end of the experiment. (C) Immune cell infiltration in injected and noninjected tumors on day 15. Tumors were stained for NK cells using anti-NK-1.1, CD4+T cells using anti-CD3 + anti-CD4, and activated CD8+T cells using anti-CD8 + anti-Granzyme B. Counted cells are represented with a corresponding bar graph for each immune cell subtype. (D) Serum levels of TNFa and IL-2. (E) Viral DNA copy number intumors treated with Ad-mlFNy-hsTGFpRII-Fc or PBS harvested on day 9. *p < 0.05; **p < 0.005; ***p < 0.0005, ns = not significant.

[0034] FIG. 11. Body weights were recorded every three days for each treatment group (6 mice per group) throughout the duration of the experiment starting on the day of the first virus injection.

[0035] FIG. 12. NK cell tumor infiltration. Immunohistochemistry staining for tumors directly inj ected with virus. Tumors were harvested on day 6 and stained for NK- 1.1 (green) and counterstained with DAPI (blue).

[0036] FIG. 13. CD3+CD4+T cell tumor infiltration. Immunohistochemistry staining for tumors directly injected with virus. Tumors were harvested on day 6 and stained for CD3 (green) and CD4 (red) and counterstained with DAPI (blue).

[0037] FIG. 14. CD8+GranzymeB+T cell tumor infiltration. Immunohistochemistry staining for tumors directly injected with virus. Tumors were harvested on day 6 and stained for GranzymeB (green) and CD8 (red) and counterstained with DAPI (blue).

[0038] FIG. 15. Verification of depletion of immune cells. (A) Schedule for treatment of C57BL / 6 mice with depletion antibodies and virus. (B) Splenocytes were harvested at various timepoints, and flow cytometry was utilized to verify depletion of CD4+and CD8+T cells (left panel) and NK cells (right panel). (C) Representative flow cytometry graphs for CD4+and CD8+T cells (upper panel) and NK cells (lower panel).

[0039] FIG. 16. Abscopal experiments. Each graph represents a single treatment group showing injected versus noninjected tumors. Data is derived from FIG. 10.

[0040] FIG. 17. NK cell tumor infiltration for abscopal experiments. Immunohistochemistry staining for injected tumors. Tumors were harvested on day 15 and stained for NK- 1.1 (red) and counterstained with DAPI (blue).

[0041] FIG. 18. NK cell tumor infiltration for abscopal experiments. Immunohistochemistry staining for noninj ected tumors. Tumors were harvested on day 15 and stained for NK- 1.1 (red) and counterstained with DAPI (blue).

[0042] FIG. 19. CD3+CD4+T cell tumor infiltration for abscopal experiments.

[0043] Immunohistochemistry staining for injected tumors. Tumors were harvested on day 15 and stained for CD3 (green) and CD4 (red) and counterstained with DAPI (blue).FIG. 20. CD3+CD4+T cell tumor infiltration for abscopal experiments.

[0044] Immunohistochemistry staining for noninjected tumors. Tumors were harvested on day 15 and stained for CD3 (green) and CD4 (red) and counterstained with DAPI (blue).

[0045] FIG. 21. CD8+GranzymeB+T cell tumor infiltration for abscopal experiments.

[0046] Immunohistochemistry staining for injected tumors. Tumors were harvested on day 15 and stained for GranzymeB (green) and CD8 (red) and counterstained with DAPI (blue).

[0047] FIG. 22. CD8+GranzymeB+T cell tumor infiltration for abscopal experiments.

[0048] Immunohistochemistry staining for noninjected tumors. Tumors were harvested on day 15 and stained for GranzymeB (green) and CD8 (red) and counterstained with DAPI (blue).

[0049] DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0050] This disclosure describes compositions and methods that exploit anti-tumor activity human T cell Immunoglobulin and Mucin-domain containing-3 (hsTIM3). In one aspect, the extracellular domain of hsTIM3 is fused to the crystallizable fragment (Fc) antibody region to form a TIM3-Fc fusion protein (hsTIM3-Fc). The presence or expression of hsTIM3-Fc in the tumor environment can inhibit tumor growth and may provide a new approach to anti-tumor therapy.

[0051] TIM3 is a protein expressed on the membrane of T cells, which are responsible for eliminating cancer cells. Various substrates bind to TIM3 and initiate TIM3 signaling. TIM3 signaling causes a decrease in T cell activity, resulting in a decreased ability of T cells to eliminate cancer cells that, in turn, allows cancer cell growth.

[0052] Pancreatic cancer is the third leading cause of cancer-related death in the United States. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. Unfortunately, most PDAC patients (-80%) are diagnosed with advanced disease where the cancer has metastasized to other organs due to a lack of any reliable biomarkers for early detection. Late diagnosis makes the disease harder to treat so that patient prognosis is typically very poor.

[0053] Existing treatments have produced only meager results. Although surgical resection is currently the only curative treatment for PDAC patients, only -20% of patients are eligible for this treatment due to the majority of PDAC patients presenting with advanced disease at the time of diagnosis. Even when surgery is an option for patients with local disease, few patients survivemore than five years post-operation. Since most patients are ineligible for surgery, the mainstay treatment option for most patients includes systemic chemotherapy with / without radiation therapy. However, the survival benefits are typically only on the order of months.

[0054] Immunotherapies, such as immune checkpoint blockage, adoptive cell therapy, and agonistic antibodies, have yielded only limited success against PD AC.

[0055] The refractory trend of PDAC to current therapeutics may be attributed to a variety of reasons. Desmoplasia is the growth of fibroblasts and deposition of extracellular matrix components, such as collagen and hyaluronic acid. This leads to the formation of dense fibrous connective tissue within tumors that are made up of both cellular and non-cellular components. The fibrous growth creates a physiological barrier that inhibits therapeutics and anti-tumor immune cells from entering the tumor nest. The immunosuppressive tumor microenvironment (TME) is characterized by the infiltration of immunosuppressive cells, such as regulatory T cells (Treg), a lack of activated T cells, and increased exhaustion of T cells. Immunosuppressive cells (e.g., Treg), along with PDAC cells, secrete immunosuppressive cytokines, such as transforming growth factor beta (TGF-P), that inhibit the function and inhibit infiltration of anti-tumor cells, promote immune evasion, and enhance tumor progression and metastasis. Consequently, the immunosuppressive tumor microenvironment is involved in the tumor’s initiation, development, and prognosis.

[0056] A viral gene delivery platform was used to express transgenes to attack PDAC.

[0057] Adenoviruses (Ad) are a commonly used virus vector backbone that can be exploited as a gene delivery tool. Given that Ad is a common viral backbone used in the clinical setting, its safety is well documented. One feature that makes Ad an attractive vector is its large packaging capacity (8 kb to 36 kb), which enables expression of various transgenes. Four transgenes were selected for express from Ads to target desmoplasia and the highly immunosuppressive tumor microenvironment in PDAC: (1) the extracellular (soluble) domain of transforming growth factor beta receptor 2 (sTGF-PRII), (2) interferon gamma (IFN-y), (3) interleukin 7 (IL-7), and (4) the extracellular domain of T cell Immunoglobulin and Mucin domain-containing protein 3 (sTIM3).

[0058] Transforming growth factor beta (TGF-P) induces several pro-tumorigenic effects after the onset of carcinogenesis in PDAC, such as desmoplasia through activation of cancer-associated fibroblasts (CAFs) and inhibition of CD8+T cell and NK cell activity. Because elevated levels of TGF-P correlate with poor prognosis, mitigating TGF-P signaling is a potentialtherapeutic target. IFN-y is involved in activating anti-tumor immune responses in cancer by promoting CD8+T cell and NK cell activation, leukocyte transportation, inflammation, cell proliferation, apoptosis, and anti -tumor effects. Increased levels of IFN-y in pancreatic cancer patients leads to better survival. Another cytokine that enhances cytotoxic T cell function is IL-7, which promotes naive and memory T cell survival, proliferation, and homeostasis. Recombinant human IL-7 is well tolerated in patients and increases CD4+and CD8+T cells. Unlike IL-2, IL-7 does not induce Treg proliferation and is less likely to cause exhaustion of cytotoxic T cells. When exhaustion does occur, checkpoint molecules, such as TIM3, show increased expression in PDAC and decrease anti-tumor T cell function. Additionally, ligands for TIM3, such as HMGB1 and galectin 9, are increased in PDAC. Therefore, inhibition of TIM3 by expressing its extracellular domain is plausible to mitigate T cell exhaustion.

[0059] This disclosure exploits the packaging capacity of Ads as a vector for the expression of four transgenes (sTGF-pRII, IFN-y, IL-7, and sTIM3) to target PDAC. These transgenes target the two main reasons why PDAC is refractory to current therapeutics: desmoplasia and the highly immunosuppressive tumor microenvironment. An immunocompetent syngeneic mouse model harboring tumors derived from KPC cells was used to see the effects these transgenes had on a fully intact immune system. Intratumoral expression of these transgenes exerts significant anti-tumor effects, reduces desmoplasia, and increases anti-tumor immune cell infiltration. This novel therapeutic approach helps shed light on how the TME can be altered to enhance clinical outcomes in PDAC patients.

[0060] In a preliminary experiment, the extracellular domain of human TIM3 (hsTIM3) was cloned and fused with the crystallizable fragment (Fc) antibody region to form a TIM3-Fc fusion protein, hsTIM3-Fc (FIG. 1). The hsTIM3-Fc fusion protein exerts anti-tumor activity by binding to substrates that would otherwise bind to the extracellular domain of TIM3 and initiate TIM3 signaling. Thus, hsTIM3-Fc competitively inhibits TIM3 signaling in T cells by binding to TIM3 substrates, reducing the availability of these substrates to TIM3, and thereby interfering with the TIM3-mediated inhibition of T cell anti-tumor activity (FIG. 2). Competitive inhibition of TIM3 signaling by hsTIM3 or hsTIM3-Fc was tested in vitro. FIG. 3 shows that hsTIM3-Fc inhibited TIM3 signaling more strongly than hsTIM or an anti-TIM3 monoclonal antibody (positive control).The hsTIM3-Fc fusion protein may be expressed by a vector — e.g., an adenovirus — that is administered to a subject — e.g., by intratumoral injection. When the adenovirus expresses hsTIM3-Fc, it is secreted into the extracellular microenvironment where it can bind to and sequester any substrates that would otherwise be available to bind to endogenous TIM3 present on T cells. With the availability of TIM3 -binding substrates reduced, TIM3 signaling in T cells is mitigated and the T cells remain in a more active state so that they can attack cancer cells. This resulted in an antitumoral effect shown in FIG. 4. Tumor volumes and tumor weights were decreased in mice that were treated with Ad-5 that expressed hsTIM3-Fc compared to tumor volumes and tumor weights in mice that were untreated (PBS) or treated with sham Ad-5 that did not express hsTIM3-Fc.

[0061] Current immunotherapies, including adoptive cellular immunotherapies, may be limited by exhaustion and / or inactivation of cytotoxic T lymphocytes (CTLs). TIM3 is an immune checkpoint, so inhibiting TIM3 signaling, thereby reducing its inhibition effects, can enhance CTL function in the tumor locale. Localized administration or expression of hsTIM3-Fc helps to mitigate pro-tumor signaling and therefore reduces the growth rate of tumors.

[0062] As noted above, TIM3 is expressed on T cells. Binding of a TIM3 substrate to TIM3 initiates TIM3 signaling in the T cell, which decreases the anti-tumor activity of the T cell.

[0063] Different TIM3 substrates bind to specific and distinct regions on TIM3. Monoclonal antibodies that reduce TIM3 signaling typically target only one region on TIM3, which leaves other binding sites available for other substrates to bind to TIM3 and thereby initiate TIM3 signaling. The presence of an hsTIM3-Fc fusion protein can sequester multiple TIM3 substrates, inhibit more than one TIM3 substrate from binding to TIM3, and therefore mitigate TIM3 signaling more broadly than by using a monoclonal antibody.

[0064] Generation and Characterization of Ad vectors with transgenes

[0065] Replication-deficient adenovirus vectors expressing mlFN-y, hsTGF-PRII-Fc, hIL-7, and hsTIM3-Fc were designed and produced (FIG. 5A). Constructs have a serotype 5 backbone, and transgene expression is driven by a cytomegalovirus (CMV) promoter. The following constructs were successfully generated: Ad-(empty) (no transgene), Ad-mlFNy, Ad-hsTGF-PRILFc, Ad-hIL-7, Ad-hsTIM3-Fc, and Ad-mlFNy-hsTGFpRII-Fc.Transgene expression was verified for each Ad construct by infecting KPC cells with increasing doses of virus and quantifying protein expression using ELISAs (FIG. 5B).

[0066] Expression of each transgene was observed in a dose-dependent manner.

[0067] Biological activity of mlFN-y, hsTGF-PRII-Fc, hIL-7, and hsTIM3-Fc were verified with separate assays using supernatants from Ad-infected KPC cells. mlFN-y decreased vesicular stomatitis virus (VSV) replication in KPC cells in a dose-dependent manner (FIG. 5C). For hsTGF-PRII-Fc, a reporter gene assay showed decreased TGF-pi signaling in the presence of hsTGF-PRII-Fc in a dose-dependent manner (FIG. 5D). Blockage of TGF-pi signaling was enhanced when hsTGF-PRII was fused to Fc. As a result, hsTGF-PRII-Fc was utilized in Ad constructs for the upcoming experiments because of the enhanced stability that the Fc fragment gives the overall protein. hIL-7 was shown to increase the proliferation of Jurkat cells (FIG. 5E). Finally, hsTIM3-Fc decreased TIM3 signaling in a reporter gene assay (FIG. 5F). Similar to hsTGF-PRII-Fc, the fusion of hsTIM3 to Fc yielded better biological activity and was therefore used in future experiments.

[0068] Anti-tumor effects of transgene-expressing Ad vectors in syngeneic mouse models

[0069] The anti-tumor effects of these transgene-expressing replication-deficient Ad constructs were tested in an immunocompetent syngeneic mouse model. As shown in FIG. 6A, 2* 106KPC cells, a commonly used mouse PDAC cell line, were subcutaneously injected into both flanks of C57BL / 6 mice. Adenovirus vector (2* IO10vp) was injected intratumorally into each tumor on day 0 and day 6. Compared to Ad-(empty), there was significant inhibition of tumor growth when tumors were treated with any of the four transgene-expressing Ad vectors, with Ad-mlFNy inducing the greatest anti-tumor effects (p = 0.000002), followed by Ad-hsTGFpRII-Fc (p = 0.0008), Ad-hIL-7 (p = 0.006), and Ad-hsTIM3-Fc (p = 0.03) (FIG. 6B). The same trend was observed with tumor weights at the endpoint of the experiment (FIG. 6C).

[0070] The vector Ad-mIFNY-hsTGFpRII-Fc (FIG. 6D) was generated to combine the antitumor effects of the two most effective transgenes. Both transgenes were expressed in a dosedependent manner (FIG. 6E), similarly to the single-transgene constructs (FIG. 5B).

[0071] Furthermore, Ad-mIFNY-hsTGFpRII-Fc showed a significant inhibition of tumor growth when compared to Ad-(empty) (p = 0.000009) and when compared to Ad-mlFNy (p = 0.04) and Ad-hsTGFpRII-Fc (p = 0.001) (FIG. 6F). The same trend was observed for tumor weights (FIG.6G). Compared to Ad-(empty), there was a significant survival rate for each transgeneexpressing Ad vector (FIG. 6H). There was no indication of any toxicity of mice when treated with any Ad constructs as noted by body weight measurements (FIG. 11) or other observations, such as visual monitoring of mice movement by veterinary staff. These results show that all four transgenes significantly inhibit tumor growth, and combining the top two transgenes in a single construct exerts the greatest anti-tumor effects.

[0072] Intratumoral Transgene Expression and Their Downstream Effects

[0073] The downstream effects from the intratumoral expression of each transgene were analyzed next. In a separate experiment done similarly as FIG. 6A, tumors were harvested at day 3 and day 6, and protein expression was quantified. Transgene expression was verified for all Ad constructs (FIG. 7A-C). Each transgene-expressing Ad vector showed significantly elevated levels of immune activation markers TNF-a (FIG. 7D) and IL-2 (FIG. 7E) by day 6. All three transgene-expressing vectors that do not express transgenic mlFN-y had significantly increased levels of IFN-y on day 3 and day 6 (FIG. 7F). Ad-hIL-7 produced increased levels of IL-ip at day 3, but increased levels of Ad-hIL-7 were not observed until day 6 for the remaining Ad constructs (FIG. 7G). All Ad constructs except Ad-mIFNy-T2A-hsTGFpRII-Fc induces an increase in both IL- 10 (FIG. 7H) and TGF-pl (FIG. 71).

[0074] To measure the decrease in TGF-P signaling, tumors harvested at day 6 were analyzed for relative levels of Suppressor of Mothers Against Decapentaplegic (SMAD) phosphorylation (FIG. 7J). Only Ad vectors expressing hsTGF-pRII-Fc showed a significant decrease in the ratio of phosphorylated SMAD (pSMAD) to total SMAD (tSMAD) (Ad-hsTGFpRII-Fc, p = 0.01; Ad-mlFNy-hsTGFpRII-Fc, p = 0.03). Furthermore, when tumors were treated with a higher dose of Ad-hsTGFpRII-Fc (6x 1010vp / tumor), there was a significant decrease in pSMAD / tSMAD when compared to the corresponding lower dose of 2* 1010vp / tumor (p = 0.01). These results indicate that there is an increased immune response when expressing each transgene, and that TGF-P signaling is decreased in the presence of hsTGF-pRII-Fc.

[0075] Intratumoral Immune Cell Infiltration Plays a Role in the Anti-tumor Effects

[0076] Tumor infiltration of immune cells was analyzed on day 6. Tissue was prepared for immunohistochemistry and stained forNK cells, CD3+CD4+T cells, and CD8+GranzymeB+activated T cells (FIG. 8A, FIG. 8B, and FIGs. 12-14). Compared to Ad-(empty), there were significantly more infiltrating NK cells and CD3+CD4+T cells when tumors were treated with Ad-mIFNy, Ad-hsTGFpRII-Fc, Ad-hIL-7, and Ad-mIFNy-hsTGFpRII-Fc. For CD8+GranzymeB+activated T cells, there was a significant increase, compared to Ad-(empty), when tumors were treated with any transgene-expressing Ad vector. Furthermore, treatment of tumors with Ad-mIFNy-hsTGFpRII-Fc yielded significantly higher infiltration of all three immune cell subsets compared to tumors treated with any Ad vector expressing a single transgene.

[0077] To gain more of a mechanistic understanding of how Ad-mIFNy-hsTGFPRII-Fc is exerting such potent antitumor effects, an immune cell depletion assay was performed to determine if the increased infiltration of NK cells, CD4+T cells, and CD8+T cells play a role in the antitumor effects. After generating subcutaneous tumors in C57BL / 6 mice, immune cells were depleted with 200 .g of depletion antibody (anti-CD4, anti-CD8, and / or anti-NK-1.1) or isotype control intraperitoneally (i.p.) on days -1 and 3, and tumors were treated with virus as performed in previous experiments. When tumors were treated with Ad-mIFNy-hsTGFpRII-Fc, individual depletion of any of the three immune cell subtypes significantly reduced anti-tumor effects compared to isotype control, with CD8+T cells (p = 0.000002) having the strongest effect followed by NK cells (p = 0.001) and CD4+T cells (p = 0.003) (FIG. 8C). Depleting all three immune cell subtypes simultaneously had the strongest effect on reducing anti-tumor effects (p = 0.00000006) compared to individual depletion, but the antitumor effect was not completely eliminated since treatment with Ad-(empty) and isotype had a higher tumor volume (FIG. 8C). A similar trend was observed for tumor weights (FIG. 8D). Overall, this shows that depletion of CD8+T cells, NK cells, and CD4+T cells significantly affects the anti-tumor response when tumors are treated with Ad-mIFNy-hsTGFpRII-Fc.

[0078] Altogether, these results show that expression of each transgene enhances intratumoral infiltration of immune cells, with Ad-mIFNy-hsTGFpRII-Fc exerting the greatest effects. Also, depleting these immune cells remarkably reduced the antitumor effect in the presence of Ad-mlFNy-hsTGFpRII-Fc.

[0079] Decrease in Fibrosis in the tumor microenvironmentTo gain further insight into the changes of the tumor microenvironment, fibrosis was analyzed on day 6. For each treatment, four tumors were analyzed and stained with Masson’s Trichrome Stain (MTS) (FIG. 9). Compared to Ad-(empty), Ad-hIL-7 (p = 0.04), Ad-hsTGFpRII-Fc (p = 0.005), Ad-mlFNy (p = 0.02), and Ad-mlFNy-hsRII-Fc (p = 0.0002) had significantly less collagen deposition (blue) (FIG. 9A, FIG. 9B) and also an increase in matrix metalloproteinase 9 (MMP9) (FIG. 9C), a prominent matrix protease. Representative images from randomly selected fields are shown in FIG. 9A. This data shows that there is a decrease in desmoplasia for the specified Ad vectors.

[0080] Ad constructs elicit abscopal effects

[0081] Considering potential effects in distant regions, the ability of Ad-mlFNy-hsTGFpRII-Fc to elicit abscopal effects was tested. Bilateral subcutaneous tumors were established with KPC cells and treated with virus as shown in FIG. 6A, and only one side was treated with virus in order to analyze abscopal effects in noninjected tumors. A significant decrease in tumor growth occurred in tumors injected with Ad-mlFNy (p = 0.00007), Ad-hsTGFpRII-Fc (p = 0.0007), and Ad-mlFNy-hsTGFpRII-Fc (p = 0.000003) (FIG. 10A, left side, FIG. 16). Furthermore, noninjected tumors had a significant decrease in tumor volume for Ad-mlFNy (p = 0.0008), Ad-hsTGFpRII-Fc (p = 0.007), and Ad-mlFNy-hsTGFpRII-Fc (p = 0.0002) (FIG. 10A, right side). Noninjected tumors in Ad-mlFNy-hsTGFpRII-Fc treated mice showed significant tumor growth inhibition when compared noninjected tumors to Ad-mfFNy treated mice (p = 0.01) and Ad-hsTGFpRII-Fc treated mice (p = 0.0008). A similar trend was observed for tumor weights (FIG.

[0082] 10B).

[0083] Immune cell infiltration of NK cells, CD3+CD4+T cells, and CD8+GranzymeB+activated T cells was measured for both injected and noninjected tumors (FIG. 10C and FIGs. 17-22). Tumors injected with all transgene-expressing Ad vectors showed a significant increase in immune cell infiltration for each analyzed immune cell compared to the Ad-(empty) vector. Tumors treated with the Ad-mlFNy-hsTGFpRII-Fc vector yielded the greatest amount of infiltration (p = 4* 10‘13forNK cells, p = 2*10'13for CD3+CD4+T cells, and p = MO'11for CD8+GranzymeB+activated T cells) (FIG. 10C). Further, noninjected tumors had a significant increase in abscopal infiltration by each immune cell subtype after the contralateral tumor was treated with a transgene-expressing Ad vector. The abscopal effect occurred with each of thetransgene-expressing Ad vectors, with Ad-mlFNy-hsTGFpRII-Fc yielding the greatest amount of infdtration (p = 1 x 10'8for NK cells, p = 1 x 10'8for CD3 CD4+T cells, and p = 3* 10'17for CD8+GranzymeB+activated T cells). Finally, noninjected tumors from treatment of the contralateral tumor with Ad-mlFNy-hsTGFpRII-Fc had significantly more NK cells and CD8+GranzymeB+activated T cells compared to noninjected tumors from treatment of a contralateral tumor with either Ad-mIFNy or Ad-hsTGFpRII-Fc. Serum levels of immune activation markers TNF-a and IL-2 show that all three Ad vectors induce systemic immunity at various timepoints, with Ad-mlFNy-hsTGFpRII-Fc exerting the greatest effects (FIG. 10D). Furthermore, no transfer of virus from injected tumors to non-injected tumors was observed (FIG. 10E). These results indicate that significant abscopal effects occur from treatment with Ad-mlFNy, Ad-hsTGFpRII-Fc, Ad-mIFNy-hsTGFpRILFc, with Ad-mIFNy-hsTGFpRILFc eliciting the greatest anti -tumor effects and immune cell infiltration in noninjected tumors.

[0084] Treatment methods

[0085] This disclosure therefore describes a novel therapy that targets desmoplasia and the highly immunosuppressive tumor microenvironment by generating Ad constructs that express one or more transgenes to overcome these obstacles. In one or more embodiments, the Ad construct expresses IFN-y. In one or more embodiments, the Ad construct expresses the extracellular domain of TGF-PRII fused to Fc (hsTGF-pRII-Fc). In one or more embodiments, the Ad construct expresses IL-7. In one or more embodiments, the Ad construct expresses the extracellular domain of TIM3 fused to Fc (hsTIM3-Fc). In one or more embodiments, the Ad construct expresses more than one of the transgenes, such as, for example, IFN-y and one or more of TGF-PRII-Fc, IL-7, or TIM3; TGF-PRII-Fc and one or more of IL-7 or TIMA; or IL-7 and TIM3. In one or more embodiments, the Ad construct expresses at least IFN-y and TGF-PRII-Fc.

[0086] While described herein in the context of exemplary embodiments in which the Ad construct expresses one or more of TGF-PRII, IFN-y, IL-7, and / or TIM3, the constructs and methods described herein can involve constructs that express any suitable transgene or combination of transgenes appropriate for a desired clinical, diagnostic, or other effect.

[0087] Exemplary alternative transgenes that may be included in constructs described herein include, but are not limited to, IL-25, an anti-PD-1 scFv, an anti-PDL-1 scFv, and TNF-a.In one or more embodiments, the transgenes are under transcription control of a CMV promoter. While described herein in the context of exemplary embodiments in which the transgenes are under transcriptional control of a CMV promotor, the Ad constructs may be designed so that the transgenes are under transcriptional control of any suitable promoter.

[0088] Exemplary alternative promoters include, but are not limited to, EFl, SRa, COX-2, and adenovirus major late, and adenovirus E3 promoters.

[0089] The transgene-expressing Ad vectors increased intratumoral levels of four immune activation markers (TNF-a, IL-2, IFN-y, and IL- 1 P) and immune cell infiltration including both CD3+CD4+T cells and NK cells, with Ad-mlFNy-hsTGFPRILFc having the greatest effects. Increased infiltration of multiple anti-tumor immune cells is promising for the clinical setting because of the nonimmunogenic nature of pancreatic ductal adenocarcinoma. TGF- signaling, represented by SMAD2 / 3 phosphorylation, was decreased in the presence of hsTGF-PRILFc compared to Ad-(empty). Inhibition of TGF-P signaling is clinically relevant because of the numerous pro-tumor effects — e.g., desmoplasia and inactivation of T cells — exerted by TGF-p.

[0090] While described herein in the context of exemplary embodiments in which the tumor being treated is pancreatic ductal adenocarcinoma (PDAC), the Ad constructs described herein can be designed to treat, and the treatment methods described herein can involve treating, other types of tumors. Exemplary tumors that may be treated include, but are not limited to, PDAC, colon cancer, lung cancer, brain tumor including glioblastoma, Malignant Peripheral Nerve Sheath Tumors (MPNST), prostate cancer, breast cancer, uterine cancer, ovarian cancer, bile duct cancer, and head-neck cancer.

[0091] While described herein in the context of exemplary embodiments in which the adenovirus backbone is Ad5, the constructs and methods described herein can involve the use of any suitable adenovirus backbone. Exemplary alternative adenovirus backbones include, but are not limited to, Ad3, Adi l, Ad26, Ad52, any other human adenovirus, any other primate adenovirus, a chimeric fiber adenovirus (e.g., Ad5 / 3 and Ad5 / 35), a targeted adenovirus (e.g., mesothelin targeted Ad5-VTIN, CD133 targeted Ad5-TYML), and a chimeric adenovirus with a targeting motif (e.g., Adi 1-5VTIN).

[0092] Targeting TGF-P by designing the Ad construct to express TGF-PRII-Fc interferes with desmoplasia in the tumor by reducing collagen deposition. IFN-y loosen extracellular matrix and IL-7 may decrease fibrosis by activating immune cells. The reduction in fibrosis caused by theexpression of any one or more of the TGF-PRIT-Fc, IFN-y, and / or IL-7 transgenes may promote the increased infdtration of immune cells seen in FIG. 8. Furthermore, the reduction in desmoplasia may allow easier access of immune cells to the tumor nest and could increase efficacy of other therapies — e.g., CAR T cells and immune checkpoint blockage — when combined with the other therapy.

[0093] The simultaneous depletion of all three immune cells (CD4+cells, CD8+cells, and NK-1.1+cells) mitigated the anti-tumor effects of treatment with transgene-expressing Ad but did not completely eliminate anti-tumor effects since treatment with Ad-(empty) and isotype antibody still had a higher volume at the end of the experiment (FIG. 8C). In addition to activating immune cells, IFN-y possesses direct killing effects on cancer cells. Thus, embodiments in which IFN-y is expressed by the Ad may attack tumors through more than one mechanism — i.e., activating immune cells and / or direct killing of tumor cells.

[0094] Since metastasis is a common cause of cancer mortality, it is beneficial for a therapeutic to act not only on primary tumors, but also act on distant metastases as well. The Ad vectors described herein suppressed growth and weight of contralateral noninjected tumors and increased immune cell infiltration compared to negative controls. These abscopal effects were not a result of virus being transferred from injected to non-injected tumors. Rather, the abscopal effects were a result of systemic activation of the immune response. Thus, the Ad constructs described herein may be used in a clinical setting where direct injection of all metastatic regions is not practical due to, for example, metastases being inaccessible to intratumoral injection, being too small to be detected (i.e. micrometastasis), or too numerous for intratumoral injection to be practical.

[0095] Thus, one or more Ad constructs engineered to express a transgene may be formulated with a pharmaceutically acceptable carrier to produce a pharmaceutical composition. When expression of more than one transgene is desired, the transgenes may be present in a single construct or may be provided in separate constructs that may be co-administered to a subject.

[0096] As used herein, “carrier” includes any solvent, dispersion medium, vehicle, coating, diluent, antibacterial, and / or antifungal agent, isotonic agent, absorption delaying agent, buffer, carrier solution, suspension, colloid, and the like. The use of such media and / or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the Ad construct, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.As used herein, “pharmaceutically acceptable” refers to a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the Ad construct without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

[0097] The Ad construct may therefore be formulated into a pharmaceutical composition. The pharmaceutical composition may be formulated in a variety of forms adapted to a preferred route of administration. Thus, a composition can be administered via known routes including, for example, intratumoral, oral, parenteral (e.g., intradermal, transcutaneous, subcutaneous, intramuscular, intravenous, intraperitoneal, etc.), or topical (e.g., intranasal, intrapulmonary, intramammary, intravaginal, intrauterine, intradermal, transcutaneous, rectally, etc.). A pharmaceutical composition can be administered to a mucosal surface, such as by administration to, for example, the nasal or respiratory mucosa (e.g., by spray or aerosol). A composition also can be administered via a sustained or delayed release.

[0098] Thus, the Ad construct may be provided in any suitable form including but not limited to a solution, a suspension, an emulsion, a spray, an aerosol, or any form of mixture. The composition may be delivered in formulation with any pharmaceutically acceptable excipient, carrier, or vehicle. For example, the formulation may be delivered in a conventional topical dosage form such as, for example, a cream, an ointment, an aerosol formulation, a non-aerosol spray, a gel, a lotion, and the like. The formulation may further include one or more additives including, but not limited to, an adjuvant, a skin penetration enhancer, a colorant, a fragrance, a flavoring, a moisturizer, a thickener, and the like.

[0099] A formulation may be conveniently presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. Methods of preparing a composition with a pharmaceutically acceptable carrier include the step of bringing the Ad construct into association with a carrier that constitutes one or more accessory ingredients. In general, a formulation may be prepared by uniformly and / or intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.

[0100] The Ad construct may be used in methods for treating a subject having a tumor. “Treat” or variations thereof refer to reducing, limiting progression, ameliorating, or resolving, to anyextent, the symptoms or signs related to a condition. A “treatment” may be therapeutic or prophylactic. “Therapeutic” and variations thereof refer to a treatment that ameliorates one or more existing symptoms or clinical signs associated with a condition. “Prophylactic” and variations thereof refer to a treatment that limits, to any extent, the development and / or appearance of a symptom or clinical sign of a condition. Generally, a “therapeutic” treatment is initiated after the condition manifests in a subject, while “prophylactic” treatment is often initiated before a condition manifests in a subject.

[0101] Treating a condition can be prophylactic or, alternatively, can be initiated after the subject exhibits one or more symptoms or clinical signs of the condition. Treatment that is prophylactic — e.g., initiated before a subject manifests a symptom or clinical sign of the condition such as, for example, while an infection remains subclinical — is referred to herein as treatment of a subject that is “at risk” of having the condition. As used herein, the term “at risk” refers to a subject that may or may not actually possess the described risk. Thus, for example, a subject “at risk” of having a condition is a subject possessing one or more risk factors associated with the condition such as, for example, genetic predisposition, ancestry, age, sex, geographical location, lifestyle, or medical history. Treatment may also be continued after symptoms have resolved, for example to delay or reduce the likelihood of recurrence.

[0102] Accordingly, a composition can be administered before, during, or after the subject first exhibits a symptom or clinical sign of the condition. Treatment initiated before the subject first exhibits a symptom or clinical sign associated with the condition may result in decreasing the likelihood that the subject experiences clinical evidence of the condition compared to a subject to which the composition is not administered, decreasing the severity of symptoms and / or clinical signs of the condition, and / or completely resolving the condition. Treatment initiated after the subject first exhibits a symptom or clinical sign associated with the condition may result in decreasing the severity of symptoms and / or clinical signs of the condition compared to a subject to which the composition is not administered, and / or completely resolving the condition.

[0103] Thus, the method includes administering an effective amount of the composition to a subject having, or at risk of having, a particular condition. In this aspect, an “effective amount” is an amount effective to reduce, limit progression, ameliorate, or resolve, to any extent, asymptom or clinical sign related to the condition. In one or more embodiments, an “effective amount” is an amount effective to decrease the size and / or weight of a tumor.

[0104] The amount of Ad construct administered can vary depending on various factors including, but not limited to, the weight, physical condition, and / or age of the subject, and / or the route of administration. Thus, the absolute amount of the Ad construct included in a given unit dosage form can vary widely, and depends upon factors such as the species, age, weight, and physical condition of the subject, and / or the method of administration. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.

[0105] In one or more embodiments, the method can include administering a sufficient amount of the Ad construct to provide a dose of, for example, from about 107viral particles (vp) to about 1013vp to the subject, although in one or more embodiments the methods may be performed by administering the Ad construct in a dose outside this range. In one or more of these embodiments, the method includes administering a sufficient amount of the Ad construct to provide a dose of from about 108vp to about 1013vp to the subject such as for example, a dose of from about 109vp to about IO10vp, a dose of from about 3x10” vp to about 3*1012vp, or a dose of from about 1011vp to about 3*1012vp.

[0106] A single dose may be administered all at once, continuously for a prescribed period of time, or in multiple discrete administrations. When multiple administrations are used, the amount of each administration may be the same or different. For example, a dose of 1012vp per day may be administered as a single administration of 1012vp, continuously over 24 hours, as two or more equal administrations (e.g., two 5xlOnvp administrations), or as two or more unequal administrations (e.g., a first administration of 7.5xlOnvp followed by a second administration of 2.5 x 1011vp). When multiple administrations are used to deliver a single dose, the interval between administrations may be the same or different.

[0107] In one or more embodiments, the active agent may be administered, for example, from a single dose to multiple doses per week, although in one or more embodiments the method can involve a course of treatment that includes administering doses of the active agent at a frequency outside this range. When a course of treatment involves administering multiple doses within a certain period, the amount of each dose may be the same or different. For example, a course of treatment can include an initial loading dose, followed by a maintenance dose that is lower thanthe loading dose. Also, when multiple doses are used within a certain period, the interval between doses may be the same or be different.

[0108] In one or more embodiments, the Ad construct may be administered from about once per month to about five times per week such as, for example, once per week, twice per week, three times per week, four times per week, or five times per week.

[0109] In one or more embodiments, the duration of treatment may range from a once-off treatment to administration of the Ad construct over the life of the subject. In one or more embodiments, the duration of treatment may be from a single once-off treatment to a duration of about two weeks or about three weeks.

[0110] In one or more embodiments, composition may be used to treat a subject suffering from cancer. As used herein, the term “cancer” refers to a group of diseases characterized by abnormal and uncontrolled cell proliferation starting at one site (primary site) with the potential to invade and to spread to other sites (secondary sites, metastases) which differentiates cancer (malignant tumor) from benign tumor. Cancers can result from many causes including genetic predisposition, viral infection, exposure to ionizing radiation, exposure to an environmental pollutant, tobacco and / or alcohol use, obesity, poor diet, lack of physical activity, or any combination thereof. As used herein, “neoplasm” or “tumor” (and grammatical variations thereof) means new and abnormal growth of tissue, which may be benign or cancerous. In a related aspect, the neoplasm is indicative of a neoplastic disease or disorder, including but not limited, to various cancers.

[0111] In one or more embodiments, the Ad construct composition is administered prior to, simultaneously with, or following chemotherapy, surgical resection of a tumor, or radiation therapy. In one or more embodiments, the Ad construct composition may be used to treat a subject having a refractory tumor. As used herein, the term “chemotherapy” or “chemotherapeutic agent” as used herein refers to any therapy or therapeutic agent used to treat cancer.

[0112] In one or more embodiments, the method further includes administering one or more additional therapeutic agents. The one or more additional therapeutic agents may be administered before, after, and / or coincident to the administration of the Ad construct. Thus, the Ad construct and any additional therapeutic agent may be co-administered. As used herein, “co-administered” refers to two or more components of a combination administered so that the therapeutic orprophylactic effects of the combination can be greater than the therapeutic or prophylactic effects of either component administered alone. Two components may be co-administered simultaneously or sequentially. Simultaneously co-administered components may be provided in one or more pharmaceutical compositions. Sequential co-admini strati on of two or more components includes cases in which the components are administered so that each component can be present at the treatment site at the same time. Alternatively, sequential co-administration of two components can include cases in which at least one component has been cleared from a treatment site, but at least one cellular effect of administering the component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site until one or more additional components are administered to the treatment site. Thus, a co-administered combination can, in certain circumstances, include components that never exist in a chemical mixture with one another. In other embodiments, the Ad construct and the additional therapeutic agent may be administered as part of a mixture or cocktail. In some aspects, the administration of the Ad construct may allow for the effectiveness of a lower dosage of other therapeutic modalities when compared to the administration of the other therapeutic agent or agents alone, thereby decreasing the likelihood, severity, and / or extent of the toxicity observed when a higher dose of the other therapeutic agent or agents is administered.

[0113] For example, the Ad construct may be used in combination with a CAR T cell composition, a check point inhibitor and / or T cell receptor engineered T cells (TCR-engineered T cell therapy).

[0114] In the preceding description and following claims, the term “and / or” means one or all of the listed elements or a combination of any two or more of the listed elements; the terms “comprises,” “comprising,” and variations thereof are to be construed as open ended — i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0115] As used herein, “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising” or the like are used in their open-ended inclusive sense, and generally mean “include, but not limited to,” “includes, but not limited to,” or “including, but not limitedto.” Further, wherever embodiments are described herein with the language “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising” and the like, otherwise analogous embodiments described in terms of “consisting of’ and / or “consisting essentially of’ are also provided. The term “consisting of’ means including, and limited to, that which follows the phrase “consisting of.” That is, “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present. The term “consisting essentially of’ indicates that any elements listed after the phrase are included, and that other elements than those listed may be included provided that those elements do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements.

[0116] As used herein, the word “exemplary” means to serve as an illustrative example and should not be construed as preferred or advantageous over other embodiments.

[0117] As used herein, the terms “preferred” and “preferably” refer to embodiments of the invention that may afford certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and is not intended to exclude other embodiments from the scope of the invention.

[0118] In the preceding description, particular embodiments may be described in isolation for clarity. Reference throughout this specification to “one embodiment,” “an embodiment,” “certain embodiments,” “one or more embodiments,” or “some embodiments,” etc., means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of such phrases in various places throughout this specification are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, features described in the context of one embodiment may be combined with features described in the context of a different embodiment except where the features are necessarily mutually exclusive.

[0119] In several places throughout the above description, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, therecited list serves only as a representative group and should not be interpreted as an exclusive list.

[0120] For any method disclosed herein that includes discrete steps, the steps may be performed in any feasible order. And, as appropriate, any combination of two or more steps may be performed simultaneously.

[0121] EXAMPLES

[0122] The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

[0123] Cell Culture

[0124] Mammalian cells were maintained in a CO2 Incubator (Thermo Fisher Scientific, Inc., Waltham, MA) at 37 °C with 5% CO2 and 80% relative humidity. KrasGV2S' ' Trp53Rl1™ ' p48-Cre (KPC) tumor cells were derived from a primary tumor from a female C57B16 / J KPC mouse with invasive and metastatic PDAC and has been previously described (Burrack et al., Cell Rep.

[0125] 2019;28:2140-2155. e6). KPC cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) / F-12 (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA) media supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Thermo Fisher Scientific, Logan, UT), lx penicillin / streptomycin (P / S) (Corning, Corning, NY), and 0.5% glucose (Alpha Teknova, Inc., Hollister, CA). 293 cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in DMEM media (Coming, Inc., Coming, NY) supplemented with 10% FBS and lx P / S. Jurkat cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in Roswell Park Memorial Institute (RPMI) (Corning, Inc., Corning, NY) media supplemented in 10% FBS and lx P / S.

[0126] Construction of Recombinant Ad vectors

[0127] Replication-deficient Ad vectors expressing each transgene were generated using the El / E3-deleted pAdEasy system (He et al., Proc Natl Acad Sci U SA. 1998;95:2509-2514). The following plasmids were purchased from Addgene (Watertown, MA): mu-IFN-y-pCIneo (#163517), pDONR223-TGFBR2 (#23623), pHAGE-CMV-hIL-7-IRES-ZsGreen-W (#26532),pCDEF3-hTIM3 (#49212), and Ncaml l 18.1-Fc-His (#72088). PCR Assembly was performed to fuse hsTGF-pRII and hsTIM3 to Fc. cDNA was cloned into the multiple cloning site (MCS) of pShuttle-CMV (He et al., Proc Natl Acad Set USA. 1998;95:2509-2514) using Kpnl / Xhol restriction sites using appropriate primers (Table 1). To generate pShuttle-CMV-mIFN-y-T2A-hsTGFpRII-Fc, the In-Fusion® HD Cloning Kit (Takara, Kyoto, Japan) was used according to the manufacturer’s protocol. Homologous recombination in BJ5183 Escherichia coli cells (Agilent Technologies, Santa Clara, CA) between pAdEasy-1 (He et al., Proc Natl Acad Sci US A. 1998;95:2509-2514) and each shuttle vector yielded each desired Ad vector.

[0128] Table 1. Primers used

[0129] Name of Primer Sequence (5' to 3 )

[0130] AGAGGTACCAGCCACCATGAACGCTACACACTGCATCTTG

[0131] mlFN-y Forward GCT (SEQ ID NO:1)

[0132] TATCTCGAGTATTCAGCAGCGACTCCTTTTCCGCTTCCT mlFN-y Reverse

[0133] (SEQ 1D NO:2) AGAGGTACCAGCCACCATGTTCCATGTTTCTTTTAGGTAT

[0134] hIL-7 Forward ATC (SEQ ID NO:3)

[0135] TATCTCGAGTATTTAGTGTTCTTTAGTGCCCATCAAAAT hlL-7 Reverse (SEQ ID NO:4)

[0136] AGAGGTACCAGCCACCATGGGTCGGGGGCTGCTCAGGGGC

[0137] hsTGF-pRII Forward CTG (SEQ ID NO:5)

[0138] TATCTCGAGTATTCAGTCAGGATTGCTGGTGTTATATTCT

[0139] hsTGF-pRII Reverse TCTGAGAA (SEQ ID NO:6)

[0140] AGAGGTACCAGCCACCATGTTTTCACATCTTCCCTTTGAC

[0141] hsTIM3 Forward TGT (SEQ ID NO:7)

[0142] TATCTCGAGTATTCAGCCTATTCTGATGGTTGCTCCAGAG

[0143] hsTIM3 Reverse TC (SEQ ID NO: 8)

[0144] PCR Assembly for hsTGF-pRII-Fc: AGAGGTACCAGCCACCATGGGTCGGGGGCTGCTCAGGGGC hsTGF-pRII Forward CTG (SEQ ID NO:9)

[0145] PCR Assembly for hsTGF-pRII-Fc: TTTGTCACAAGACTTTGGCTCGACGTCAGGATTGCTGGTG hsTGF-pRII Reverse TTATATTCTTCTGAGAA (SEQ ID NO: 10)

[0146] PCR Assembly for hsTGF-pRII-Fc: GTCGAGCCAAAGTCTTGTGACAAAACTCACACA (SEQ ID hFc Forward NO: 11)

[0147] PCR Assembly for hsTGF-pRII-Fc: TATCTCGAGTATTCATTTACCCGGAGACAGGGAGAGGCTC hFc Reverse TTCTG (SEQ ID NO: 12)

[0148]

[0149] PCR Assembly for hsTIM3-Fc: AGAGGTACCAGCCACCATGTTTTCACATCTTCCCTTTGAC hsTIM3 Forward TGT (SEQ ID NO: 13)

[0150] PCR Assembly for hsTIM3-Fc: TTTGTCACAAGACTTTGGCTCGACGCCTATTCTGATGGTT hsTlM3 Reverse GCTCCAGAGTC (SEQ ID NO:14)

[0151] PCR Assembly for hsTIM3-Fc: hFc GTCGAGCCAAAGTCTTGTGACAAAACTCACACA (SEQ ID Forward NO:15)

[0152] PCR Assembly for hsTIM3-Fc: hFc TATCTCGAGTATTCATTTACCCGGAGACAGGGAGAGGCTC Reverse TTCTG (SEQ ID NO: 16)

[0153] In-Fusion for mlFN-y-hsTGF-pRII- ATC CGCTAG AG ATCTGGTACC AG CCAC CATG AACG CTAC A Fc: mIFN-y Forward CACTGCATCTTGGCTTTG (SEQ ID NO: 17)

[0154] tgggccaggattctcctcgacgtcaccgcatgttagcaga In-Fusion for mIFN-y-hsTGF-[3RII- cttcctctgccctCcccggagcCGCAGCGACTCCTTTTCC Fc: mIFN-y-T2A Reverse GCTTCCTGAGGCT (SEQ ID NO: 18)

[0155] In-Fusion formIFN-y-hsTGF-pRII- gtcgaggagaatcctggcccaATGGGTCGGGGGCTGCTCA Fc: hsTGF-pRII-Fc Forward GGGGCCTGTGGCCGCTGCAC (SEQ ID NO: 19)

[0156] In-Fusion formIFN-y-hsTGF-pRII- ATCTAGAAGCTTAGGCTCGAGTATTCATTTACCCGGAGAC Fc: hsTGF-pRII-Fc Reverse AGGGAGAGGCTCTTCTG (SEQ ID NO:20)

[0157] E4 Forward GGAGTGCGCCGAGACAAC (SEQ ID NO:21)

[0158] E4 Reverse ACTACGTCCGGCGTTCCAT (SEQ ID NO:22)

[0159]

[0160] Virus Amplification, Purification, and Quantification:

[0161] Amplification of viral particles was performed in the El -transcomplementing cell line, 293, by first transfecting Ad vectors into cells and then using the crude viral lysates (CVLs) to perform serial amplification steps (Davydova et al., Curr Protoc Hum Genet. 2013;Chapter 12:Unit 12.14). Mature viral particles were purified from the CVL using double CsCl banding. Aliquots of virus were quantified for viral particle titer (absorbance at 260 nm) and plaque forming unit (pfu) assays (Davydova et al., Curr Protoc Hum Genet. 2013;Chapter 12:Unit 12.14).

[0162] Quantification of Intratumoral Protein and Viral DNA

[0163] Using a 12-well plate, l*105KPC cells were infected with 1 vp / cell, 10 vp / cell, 100 vp / cell, or 1,000 vp / cell. Supernatants were collected 72 hours post-infection, spun down at 14,000xg for 10 minutes at 4 °C, aliquoted, and stored at -80 °C.To prepare tumor homogenates, tumors were harvested, washed in PBS, weighed, and frozen at -80 °C. On the day of homogenization, tumors were thawed on ice and placed in a homogenizer tube (KIMBLE BIOMASHER II , DWK Life Sciences, Wertheim, Germany) with 700 pL PBS. Tissue was cut into fine pieces and homogenized with the pestle for 60 seconds. Samples were spun down at 14,000xg for 10 minutes at 4 °C, and supernatants were transferred to a new tube. Samples were spun down once more, and supernatants were aliquoted and stored at -80 °C.

[0164] To prepare serum samples, cheek blood was collected from mice and allowed to coagulate overnight at 4 °C. Coagulated blood was spun down at 8,000 g for 10 minutes, and serum was stored at -80 °C.

[0165] Enzyme-Linked Immunosorbent Assays (ELISA) kits were used according to the manufacturers’ protocol (Table 2).Table 2. ELTSA kits used

[0166] W

[0167] m W

[0168]

[0169] Viral DNA was extracted from frozen tumors using the QIAamp DNA Mini Kit (Qiagen N.V., Venlo, The Netherlands). The total viral copy number was analyzed using E4 primers (Table 1) and SYBRGreen quantitative PCR (qPCR).

[0170] Biological Activity Assays

[0171] mlFN-y - anti-viral assay: Inhibition of vesicular stomatitis virus (VSV) replication by mlFN-y supernatants was tested using a VSV virus expressing GFP (VSV-GFP) (Vogel et al., Curr Protoc Immunol. 2001;Chapter 6:Unit 6.9).

[0172] hsTGF-PRII-Fc - TGF-0 Signal Blockage Assay: Blockage of TGF- 1 signaling by hsTGF-PRII-Fc supernatants was tested using a reporter assay kit (Invivogen, San Diego, CA,) according to the manufacturer’s protocol.

[0173] hIL-7 - T cell Proliferation Assay: Enhancement of T cell proliferation by hIL-7 supernatants was tested using an MTS assay with Jurkat cells (Namen et al., Curr Protoc Immunol. 2001;Chapter 6:Unit 6.7).

[0174] hsTIM3-Fc - TIM3 Signal Blockage Assay: Blockage of TIM3 signaling by hsTIM3-Fc supernatants was tested using a reporter assay kit (Promega, Madison, WI) according to the manufacturer’s protocol.

[0175] Animal Maintenance

[0176] C57BL / 6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota. Mice were housed and maintained by the Research Animal Resources (RAR) staff. RAR laboratory animal veterinarians oversaw the well-being and clinical care of animals.

[0177] Subcutaneous Tumor Generation, Measurement, and Injections

[0178] Subcutaneous tumors were generated by injecting 2x 106KPC cells suspended in 100 pL of PBS into the left and right flanks of C57BL / 6 mice. Tumor volume was acquired using digital calipers and the following formula: tumor volume = (length *width2) / 2. When tumors became -100 mm3(-10-12 days), Ad vector (2x 1010vp in 50 pL PBS) was injected intratumorally intoboth tumors on day 0 and again on day 6. For abscopal experiments, only the left tumor was treated.

[0179] For immune cell depletion analysis, 200 pg of depletion antibody or isotype control (Table 2) diluted in 100 pL of PBS was injected intraperitoneally on day -1 and day 3. To verify depletion of immune cells, splenocytes were isolated from three different mice on day 0, day 3, and 15 (Stachowiak et al., Oncoimmurtology . 2025;14:2521392). Splenocytes were stained for CD4+and CD8+T cells as well as NK cells (FIG. 15) and analyzed by flow cytometry (FACS CANTO II, BD Biosciences, Franklin Lakes, NJ).

[0180] Immunohistochemistry and Fibrosis Quantification

[0181] Formalin-fixed paraffin embedded (FFPE) tissue sections of 4 pm thickness were stained with appropriate antibodies (Table 2) and imaged with a 40x objective lens using the fluorescence microscope (BZ-X810; Keyence, Osaka, Japan). Each treatment group had four tumors, and five random fields were captured per tumor (n = 20 images per group).

[0182] To quantify fibrosis, tissue sections were stained with Mason’s Trichrome Stain. Whole tumor section images were acquired by stitching individual images together. The BZ-X800 analyzer software (Keyence, Osaka, Japan) was used to quantify the total tumor section area and blue (collagen) pigmentation within the total tumor section area by creating masked images. Fibrosis was represented as the percentage of blue pigmentation within the total tumor area. Four separate tumors were analyzed for each treatment group.

[0183] Statistical Analysis

[0184] Statistical analysis was performed using statistical spreadsheet software (EXCEL, Microsoft, Redmond, WA, USA). Comparisons between two groups were performed using two-tailed unpaired Student’s t tests. Results are expressed as mean ± SD, and differences with p < 0.05 were considered statistically significant.

[0185] The complete disclosure of all patents, patent applications, and publications, and electronically available material (including, for instance, nucleotide sequence submissions in, e.g., GenBank and RefSeq, and amino acid sequence submissions in, e.g., SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) cited herein areincorporated by reference in their entirety. Tn the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

[0186] Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0187] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements.

[0188] All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.

Claims

What is claimed is:

1. A fusion protein comprising:a human T cell immunoglobulin and mucin-domain containing-3 (TIM-3) extracellular domain; andan Fc antibody region domain.

2. A fusion protein comprising:a human transforming growth factor beta receptor 2 (TGF-0RII) extracellular domain; andan Fc antibody region domain.

3. A vector engineered to express the fusion protein of claim 1 or claim 2.

4. An adenovirus comprising a polynucleotide that encodes the fusion protein of claim 1 or claim 2.

5. A pharmaceutical composition comprising:the fusion protein of claim 1 or the fusion protein of claim 2; anda pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising:the vector of claim 3 or the adenovirus of claim 4; anda pharmaceutically acceptable carrier.

7. A method of treating a subject having a tumor, the method comprising administering to the subject the pharmaceutical composition of claim 5 or claim 6 in an amount effective to reduce the size of the tumor.

8. A method of treating a subject having a tumor, the method comprising administering to the subject the pharmaceutical composition of claim 5 or claim 6 in an amount effective to reduce the weight of the tumor.

9. The method of claim 7 or claim 8, wherein the tumor is a pancreatic cancer tumor.

10. An adenovirus comprising at least ofa polynucleotide encoding human interferon gamma (hlFN-y);a polynucleotide encoding an extracellular domain of transforming growth factor beta receptor 2 (TGF-PRII-Fc);a polynucleotide encoding IL-7; ora polynucleotide encoding T cell immunoglobulin and mucin-domain containing-3 (TIM-3).

11. The adenovirus of claim 10, wherein the polynucleotide encoding hlFN-y and the polynucleotide encoding TGF-PRII-Fc are operably linked to a cytomegalovirus (CMV) promoter.

12. The adenovirus of claim 10 or claim 11, comprising:a polynucleotide encoding human interferon gamma (hlFN-y); anda polynucleotide encoding an extracellular domain of transforming growth factor beta receptor 2 (TGF-PRII-Fc).

13. A method of treating a tumor in a subject, the method comprising administering the adenovirus of any one of claims 10-12 to the subject in an amount effective for treating the tumor.

14. The method of claim 13, wherein the tumor is a refractory tumor.

15. The method of claim 14, wherein the refractory tumor is pancreatic ductal adenocarcinoma (PDAC).

16. The method of any one of claims 13-15, further comprising administering to the subject an additional anti-tumor therapy.

17. The method of claim 16, wherein the additional anti -tumor therapy comprises CAR T cells, a check point inhibitor, or T cell receptor engineered T cells.

18. A polypeptide comprising the amino acid sequence of SEQ ID NO:23.

19. A polypeptide comprising the amino acid sequence of SEQ ID NO:24.